ReviewNature reviews. Cardiology2012
Diagnosis and management of Chagas disease and cardiomyopathy.
Review in Nature reviews. Cardiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 165 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
165 citing papers in PubMed, 7 syntheses or guidelines pooled it, 328 citations in OpenAlex.
- SBC Guideline on the Diagnosis and Treatment of Patients with Cardiomyopathy of Chagas Disease - 2023.Arquivos brasileiros de cardiologia · 2023Guideline
- Risk Factors for Progression to Chronic Chagas Cardiomyopathy: A Systematic Review and Meta-Analysis.The American journal of tropical medicine and hygiene · 2023Pooled it
- Galectin-3 and fibrosis intensity in Chronic Chagas Cardiomyopathy: a systematic review.Revista do Instituto de Medicina Tropical de Sao Paulo · 2022Pooled it
- The health-related quality of life in patients with Chagas disease: the state of the art.Revista da Sociedade Brasileira de Medicina Tropical · 2022Pooled it
- Anti-inflammatory and antioxidant therapies for chagasic myocarditis: a systematic review.Parasitology · 2020Pooled it
- Amiodarone for arrhythmia in patients with Chagas disease: A systematic review and individual patient data meta-analysis.PLoS neglected tropical diseases · 2018Pooled it
- Pharmacological interventions for treating heart failure in patients with Chagas cardiomyopathy.The Cochrane database of systematic reviews · 2016 · on this mapPooled it
- Two-year death prediction models among patients with Chagas Disease using machine learning-based methods.PLoS neglected tropical diseases · 2022Trial
- Omega-3 supplementation on inflammatory markers in patients with chronic Chagas cardiomyopathy: a randomized clinical study.Nutrition journal · 2017Trial
- Trial
- Electrocardiographic Abnormalities and Treatment with Benznidazole among Children with Chronic Infection by Trypanosoma cruzi: A Retrospective Cohort Study.PLoS neglected tropical diseases · 2016Trial
- Effects of exercise training on heart rate variability in Chagas heart disease.Arquivos brasileiros de cardiologia · 2014Trial
- Trial
- Endothelial transmigration by Trypanosoma cruzi.PloS one · 2013Trial
- The Utility of Microbial Cell-Free DNA in the Rapid Diagnosis of Chagas Disease: Chagas Disease Case Series.Open forum infectious diseases · 2026Article
- Chagas in Children Unmasked With Multimodality Imaging.JACC. Case reports · 2026Article
- AI-ECG for Detecting Left Ventricular Systolic Dysfunction in Chagas Disease: Diagnostic and Prognostic Value.JACC. Advances · 2026Article
- Serum Proteomics Provides Novel Biomarkers of Inflammation, Tissue Injury, and Therapeutic Response in Experimental Chagas Disease.Microorganisms · 2026Article
- Long-Term Parasitological Clearance and Cardiac Progression inTropical medicine and infectious disease · 2026Article
- Implantation of Pacemakers in Patients with Chagas disease: A Case-Control Study of Associated Contextual Factors and Prognosis.Arquivos brasileiros de cardiologia · 2026Article
105 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chagas cardiomyopathy is the most severe and life-threatening manifestation of human Chagas disease--a 'neglected' tropical disease caused by the protozoan parasite Trypanosoma cruzi. The disease is endemic in all continental Latin American countries, but has become a worldwide problem because of migration of infected individuals to developed countries, mainly in Europe and North America. Chagas cardiomyopathy results from the combined effects of persistent parasitism, parasite-driven tissue inflammation, microvascular and neurogenic dysfunction, and autoimmune responses triggered by the infection. Clinical presentation varies widely according to the extent of myocardial damage, and manifests mainly as three basic syndromes that can coexist in an individual patient: heart failure, cardiac arrhythmia, and thromboembolism. NYHA functional class, left ventricular systolic function, and nonsustained ventricular tachycardia are important prognostic markers of the risk of death. Management of Chagas cardiomyopathy focuses on the treatment of the three main syndromes. The use of β-blockers in patients with Chagas disease and heart failure is safe, well tolerated, and should be encouraged. Most specialists and international institutions now recommend specific antitrypanosomal treatment of patients with chronic Chagas disease, even in the absence of evidence obtained from randomized clinical trials. Further research on the management of patients with Chagas cardiomyopathy is necessary.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.